You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameThalidomide
Accession NumberDB01041  (APRD01251)
TypeSmall Molecule
GroupsApproved, Investigational, Withdrawn
DescriptionA piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
Structure
Thumb
Synonyms
(+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide
(+-)-Thalidomide
(±)-N-(2,6-dioxo-3-piperidyl)phthalimide
(±)-thalidomide
1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline
2,6-dioxo-3-phthalimidopiperidine
3-Phthalimidoglutarimide
alpha-(N-Phthalimido)glutarimide
alpha-N-Phthalylglutaramide
N-(2,6-dioxo-3-piperidyl)phthalimide
N-Phthaloylglutamimide
N-Phthalyl-glutaminsaeure-imid
N-Phthalylglutamic acid imide
Talidomida
Thalidomidum
α-(N-phthalimido)glutarimide
α-N-phthalylglutaramide
α-phthalimidoglutarimide
External Identifiers
  • NSC-527179
  • NSC-66847
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Thalidomide CelgeneCapsule, hard50 mgOral useCelgene Europe Limited  2008-04-16Not applicableEu
Thalomidcapsule50 mgoralCelgene Inc2010-11-01Not applicableCanada
Thalomidcapsule50 mg/1oralCelgene Corporation2003-06-20Not applicableUs
Thalomidcapsule100 mgoralCelgene Inc2011-02-17Not applicableCanada
Thalomidcapsule100 mg/1oralCelgene Corporation2003-06-20Not applicableUs
Thalomidcapsule200 mgoralCelgene Inc2011-02-17Not applicableCanada
Thalomidcapsule150 mg/1oralCelgene Corporation2007-03-20Not applicableUs
Thalomidcapsule150 mgoralCelgene IncNot applicableNot applicableCanada
Thalomidcapsule200 mg/1oralCelgene Corporation2003-06-20Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ConterganNot Available
DistavalNot Available
K-17Not Available
Pro-ban MNot Available
SedalisNot Available
SoftenonNot Available
TalimolNot Available
ThaledNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4Z8R6ORS6L
CAS number50-35-1
WeightAverage: 258.2295
Monoisotopic: 258.064056818
Chemical FormulaC13H10N2O4
InChI KeyInChIKey=UEJJHQNACJXSKW-UHFFFAOYSA-N
InChI
InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
IUPAC Name
2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
SMILES
O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoindoles and derivatives
Sub ClassIsoindolines
Direct ParentIsoindolones
Alternative Parents
Substituents
  • Isoindolone
  • Isoindole
  • Piperidinedione
  • Piperidinone
  • Dicarboximide
  • Delta-lactam
  • 3-aminopiperidine
  • Benzenoid
  • Piperidine
  • Carboxylic acid imide, n-unsubstituted
  • Carboxylic acid imide
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
PharmacodynamicsThalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans.
Mechanism of actionIn patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration. For example, administration of thalidomide has been reported to decrease circulating levels of TNF-a in patients with ENL, however, it has also been shown to increase plasma TNF-a levels in HIV-seropositive patients. As a cancer treatment, the drug may act as a VEGF inhibitor.
Related Articles
AbsorptionThe absolute bioavailability has not yet been characterized in human subjects due to its poor aqueous solubility. In studies of both healthy volunteers and subjects with Hansen’s disease, the mean time to peak plasma concentrations (Tmax) ranged from 2.9 to 5.7 hours indicating that thalidomide is slowly absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein binding55% and 66% for the (+)R and (−)S enantiomers, respectively.
Metabolism

Thalidomide itself does not appear to be hepatically metabolized to any large extent, but appears to undergo non-enzymatic hydrolysis in plasma to multiple metabolites. Thalidomide may be metabolized hepatically by enzymes of the cytochrome P450 enzyme system. The end product of metabolism, phthalic acid, is excreted as a glycine conjugate.

SubstrateEnzymesProduct
Thalidomide
cis, trans-5'-HydroxythalidomideDetails
Thalidomide
5-HydroxythalidomideDetails
Thalidomide
Thalidomide arene oxideDetails
Thalidomide arene oxide
Not Available
5-HydroxythalidomideDetails
5-Hydroxythalidomide
5,6-dihydroxythalidomideDetails
Thalidomide
Not Available
4-phthalimidoglutaramic acidDetails
Thalidomide
Not Available
2-phthalimidoglutaramic acidDetails
2-phthalimidoglutaramic acid
Not Available
2-phthalimidoglutaric acidDetails
4-phthalimidoglutaramic acid
Not Available
2-phthalimidoglutaric acidDetails
Thalidomide
Not Available
alpha-(o-carboxybenzamido)glutarimideDetails
4-phthalimidoglutaramic acid
Not Available
4-(o-carboxybenzamido)glutaramic acidDetails
2-phthalimidoglutaramic acid
Not Available
2-(o-carboxybenzamido)glutaramic acidDetails
alpha-(o-carboxybenzamido)glutarimide
Not Available
2-(o-carboxybenzamido)glutaramic acidDetails
4-(o-carboxybenzamido)glutaramic acid
Not Available
2-(o-carboxybenzamido)glutaric acidDetails
4-(o-carboxybenzamido)glutaramic acid
Not Available
2-(o-carboxybenzamido)glutaric acidDetails
2-(o-carboxybenzamido)glutaramic acid
Not Available
2-(o-carboxybenzamido)glutaric acidDetails
Route of eliminationThalidomide itself has less than 0.7% of the dose excreted in the urine as unchanged drug.
Half lifeThe mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.
ClearanceNot Available
ToxicityThe R-configuration and the S-configuration are more toxic individually than the racemic mixture. The LD50 could not be established in mice for racemic thalidomide, whereas LD50 values for the R and S configurations are reported to be 0.4 to 0.7 g/kg and 0.5 to 1.5 g/kg, respectively.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9775
Blood Brain Barrier+0.9382
Caco-2 permeable-0.5651
P-glycoprotein substrateSubstrate0.5301
P-glycoprotein inhibitor INon-inhibitor0.5115
P-glycoprotein inhibitor IINon-inhibitor0.8951
Renal organic cation transporterNon-inhibitor0.8179
CYP450 2C9 substrateNon-substrate0.7904
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5309
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9378
BiodegradationNot ready biodegradable0.8838
Rat acute toxicity3.3039 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9769
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsule, hardOral use50 mg
Capsuleoral100 mg/1
Capsuleoral100 mg
Capsuleoral150 mg
Capsuleoral150 mg/1
Capsuleoral200 mg/1
Capsuleoral200 mg
Capsuleoral50 mg/1
Capsuleoral50 mg
Prices
Unit descriptionCostUnit
Thalomid 28 50 mg capsule Disp Pack4372.47USD disp
Thalomid 200 mg capsule277.5USD capsule
Thalomid 150 mg capsule260.61USD capsule
Thalomid 100 mg capsule243.73USD capsule
Thalomid 50 mg capsule150.15USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2157288 No2005-11-082014-02-24Canada
CA2505964 No2009-07-282023-11-13Canada
US6045501 No1998-08-282018-08-28Us
US6235756 No1993-03-012013-03-01Us
US6315720 No2000-10-232020-10-23Us
US6561976 No1998-08-282018-08-28Us
US6561977 No2000-10-232020-10-23Us
US6755784 No2000-10-232020-10-23Us
US6869399 No2000-10-232020-10-23Us
US6908432 No1998-08-282018-08-28Us
US7141018 No2000-10-232020-10-23Us
US7230012 No2003-12-092023-12-09Us
US7435745 No1997-11-032017-11-03Us
US7874984 No1998-08-282018-08-28Us
US7959566 No2000-10-232020-10-23Us
US8204763 No1998-08-282018-08-28Us
US8315886 No2000-10-232020-10-23Us
US8589188 No1998-08-282018-08-28Us
US8626531 No2000-10-232020-10-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point270 °CPhysProp
water solubility545 mg/L (at 25 °C)BUDAVARI,S ET AL. (1996)
logP0.33HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility2.55 mg/mLALOGPS
logP0.42ALOGPS
logP0.016ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)11.59ChemAxon
pKa (Strongest Basic)-6.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area83.55 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity64.32 m3·mol-1ChemAxon
Polarizability24.42 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0wba-4900000000-77362eaf27267f59650dView in MoNA
References
Synthesis Reference

Jamshed Shah, “Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs.” U.S. Patent US20030139451, issued July 24, 2003.

US20030139451
General ReferencesNot Available
External Links
ATC CodesL04AX02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (180 KB)
MSDSDownload (58.6 KB)
Interactions
Drug Interactions
Drug
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thalidomide is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Thalidomide can be increased when it is combined with Abiraterone.
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AcepromazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Acepromazine.
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AceprometazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Aceprometazine.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Thalidomide.
adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
adipiplonThe risk or severity of adverse effects can be increased when Thalidomide is combined with adipiplon.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AgomelatineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Agomelatine.
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Alfaxalone.
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AlfentanilThe risk or severity of adverse effects can be increased when Thalidomide is combined with Alfentanil.
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Alphacetylmethadol.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AlprazolamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Alprazolam.
AmiodaroneThe metabolism of Thalidomide can be decreased when combined with Amiodarone.
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AmisulprideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amisulpride.
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AmitriptylineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amitriptyline.
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AmobarbitalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amobarbital.
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AmoxapineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amoxapine.
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AmperozideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amperozide.
AprepitantThe metabolism of Thalidomide can be increased when combined with Aprepitant.
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AripiprazoleThe risk or severity of adverse effects can be increased when Thalidomide is combined with Aripiprazole.
ArmodafinilThe metabolism of Thalidomide can be decreased when combined with Armodafinil.
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ArticaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Articaine.
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AsenapineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Asenapine.
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AzaperoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Azaperone.
AzelastineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
AzithromycinThe metabolism of Thalidomide can be decreased when combined with Azithromycin.
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BaclofenThe risk or severity of adverse effects can be increased when Thalidomide is combined with Baclofen.
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BarbitalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Barbital.
BazedoxifeneBazedoxifene may increase the thrombogenic activities of Thalidomide.
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BenzocaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Benzocaine.
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Thalidomide is combined with Benzyl alcohol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Thalidomide.
BortezomibThe metabolism of Thalidomide can be decreased when combined with Bortezomib.
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Thalidomide is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BrimonidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Brimonidine.
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BromazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Bromazepam.
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BrompheniramineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Brompheniramine.
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BrotizolamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Brotizolam.
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BupivacaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Bupivacaine.
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BuprenorphineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Buprenorphine.
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
BuspironeThe risk or severity of adverse effects can be increased when Thalidomide is combined with Buspirone.
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ButabarbitalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Butabarbital.
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ButacaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Butacaine.
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ButalbitalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Butalbital.
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ButambenThe risk or severity of adverse effects can be increased when Thalidomide is combined with Butamben.
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ButethalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Butethal.
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ButorphanolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Butorphanol.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thalidomide.
CaffeineThe metabolism of Thalidomide can be decreased when combined with Caffeine.
CapecitabineThe metabolism of Thalidomide can be decreased when combined with Capecitabine.
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CarbamazepineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Carbamazepine.
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CarbinoxamineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Carbinoxamine.
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CarfentanilThe risk or severity of adverse effects can be increased when Thalidomide is combined with Carfentanil.
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CarisoprodolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Carisoprodol.
CeritinibThe serum concentration of Thalidomide can be increased when it is combined with Ceritinib.
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CetirizineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cetirizine.
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Chloral hydrateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Thalidomide can be decreased when combined with Chloramphenicol.
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chlordiazepoxide.
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chlormezanone.
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ChloroprocaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chloroprocaine.
ChlorotrianiseneChlorotrianisene may increase the thrombogenic activities of Thalidomide.
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chlorphenamine.
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ChlorpromazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chlorpromazine.
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chlorprothixene.
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Thalidomide can be decreased when combined with Cholecalciferol.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Thalidomide.
CimetidineThe metabolism of Thalidomide can be decreased when combined with Cimetidine.
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CinchocaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Thalidomide is combined with Citalopram.
CitalopramThe metabolism of Thalidomide can be decreased when combined with Citalopram.
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ClemastineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clemastine.
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ClidiniumThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clidinium.
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ClobazamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clobazam.
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
clomethiazoleThe risk or severity of adverse effects can be increased when Thalidomide is combined with clomethiazole.
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ClomipramineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clomipramine.
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ClonazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clonazepam.
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ClonidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clonidine.
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ClorazepateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clorazepate.
ClotrimazoleThe metabolism of Thalidomide can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clozapine.
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CocaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cocaine.
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CodeineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Codeine.
Conjugated Equine EstrogensConjugated Equine Estrogens may increase the thrombogenic activities of Thalidomide.
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CyclizineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cyclizine.
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cyclobenzaprine.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Thalidomide.
CyclosporineThe metabolism of Thalidomide can be decreased when combined with Cyclosporine.
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
CyproheptadineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Thalidomide can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Thalidomide can be decreased when it is combined with Dabrafenib.
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DantroleneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dantrolene.
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DapiprazoleThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dapoxetine.
Darbepoetin alfaDarbepoetin alfa may increase the thrombogenic activities of Thalidomide.
DeferasiroxThe serum concentration of Thalidomide can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Thalidomide can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Thalidomide.
deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
deramciclaneThe risk or severity of adverse effects can be increased when Thalidomide is combined with deramciclane.
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DesfluraneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Desflurane.
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DesipramineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Thalidomide.
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DesloratadineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Desloratadine.
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DetomidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Detomidine.
DexamethasoneDexamethasone may increase the dermatologic adverse activities of Thalidomide.
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dexbrompheniramine.
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dexmedetomidine.
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DextromoramideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dextromoramide.
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dextropropoxyphene.
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DezocineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dezocine.
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DiazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Diazepam.
DienestrolDienestrol may increase the thrombogenic activities of Thalidomide.
DiethylstilbestrolDiethylstilbestrol may increase the thrombogenic activities of Thalidomide.
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DifenoxinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Difenoxin.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Thalidomide.
DigoxinDigoxin may decrease the cardiotoxic activities of Thalidomide.
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DihydrocodeineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dihydrocodeine.
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dihydroetorphine.
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DihydromorphineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dihydromorphine.
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DimenhydrinateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dimenhydrinate.
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DiphenhydramineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Diphenhydramine.
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DiphenoxylateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Diphenoxylate.
DisulfiramThe metabolism of Thalidomide can be decreased when combined with Disulfiram.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thalidomide.
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DoramectinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Doramectin.
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DoxepinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DoxylamineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Doxylamine.
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DPDPEThe risk or severity of adverse effects can be increased when Thalidomide is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DroperidolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Droperidol.
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DrotebanolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Drotebanol.
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DyclonineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dyclonine.
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EcgonineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ecgonine.
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Thalidomide is combined with ECGONINE METHYL ESTER.
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EfavirenzThe risk or severity of adverse effects can be increased when Thalidomide is combined with Efavirenz.
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EnfluraneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Enflurane.
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EntacaponeThe risk or severity of adverse effects can be increased when Thalidomide is combined with Entacapone.
ErythropoietinErythropoietin may increase the thrombogenic activities of Thalidomide.
EscitalopramThe risk or severity of adverse effects can be increased when Thalidomide is combined with Escitalopram.
Eslicarbazepine acetateThe metabolism of Thalidomide can be decreased when combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Thalidomide can be decreased when combined with Esomeprazole.
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EstazolamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Estazolam.
EstradiolEstradiol may increase the thrombogenic activities of Thalidomide.
EstriolEstriol may increase the thrombogenic activities of Thalidomide.
EstroneEstrone may increase the thrombogenic activities of Thalidomide.
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EszopicloneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Eszopiclone.
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EthchlorvynolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethchlorvynol.
Ethinyl EstradiolEthinyl Estradiol may increase the thrombogenic activities of Thalidomide.
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EthosuximideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethosuximide.
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EthotoinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethotoin.
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethyl carbamate.
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethyl loflazepate.
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EthylmorphineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethylmorphine.
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EtidocaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etidocaine.
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EtifoxineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etifoxine.
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EtizolamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etizolam.
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EtomidateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etomidate.
EtoperidoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etoperidone.
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EtorphineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etorphine.
EtravirineThe metabolism of Thalidomide can be decreased when combined with Etravirine.
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
EzogabineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ezogabine.
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FelbamateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Felbamate.
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FencamfamineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fenfluramine.
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FentanylThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fentanyl.
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FexofenadineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fexofenadine.
FingolimodThalidomide may increase the immunosuppressive activities of Fingolimod.
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FlibanserinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Flibanserin.
FloxuridineThe metabolism of Thalidomide can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Thalidomide can be decreased when combined with Fluconazole.
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FludiazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fludiazepam.
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FlunarizineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Flunarizine.
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FlunitrazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Flunitrazepam.
FluorouracilThe metabolism of Thalidomide can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fluoxetine.
FluoxetineThe metabolism of Thalidomide can be decreased when combined with Fluoxetine.
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FlupentixolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Flupentixol.
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FluphenazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fluphenazine.
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FlurazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Flurazepam.
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FluspirileneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fluspirilene.
Fluticasone PropionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Thalidomide can be decreased when combined with Fluvastatin.
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FluvoxamineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fluvoxamine.
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FosphenytoinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fosphenytoin.
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
FospropofolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fospropofol.
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
GabapentinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Gabapentin.
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Thalidomide is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Thalidomide is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Thalidomide can be decreased when combined with Gemfibrozil.
GenisteinGenistein may increase the thrombogenic activities of Thalidomide.
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
GlutethimideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Glutethimide.
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
GuanfacineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Guanfacine.
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
HalazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Halazepam.
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
HaloperidolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Haloperidol.
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
HalothaneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Halothane.
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
HeroinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Heroin.
HexestrolHexestrol may increase the thrombogenic activities of Thalidomide.
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
HexobarbitalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hexobarbital.
HydrocodoneHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
HydrocodoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hydrocodone.
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
HydromorphoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
HydroxyzineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hydroxyzine.
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
IloperidoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Iloperidone.
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ImipramineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Indalpine.
IndinavirThe metabolism of Thalidomide can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Thalidomide can be decreased when combined with Irbesartan.
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
IsofluraneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Isoflurane.
IsoniazidThe metabolism of Thalidomide can be decreased when combined with Isoniazid.
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
KetamineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ketamine.
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
KetazolamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ketazolam.
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
KetobemidoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ketobemidone.
KetoconazoleThe metabolism of Thalidomide can be decreased when combined with Ketoconazole.
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LamotrigineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Lamotrigine.
LeflunomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Leflunomide.
LeflunomideThe metabolism of Thalidomide can be decreased when combined with Leflunomide.
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levetiracetam.
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LevobupivacaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levobupivacaine.
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LevocabastineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levocabastine.
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LevocetirizineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levocetirizine.
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LevodopaThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levodopa.
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levomilnacipran.
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LevorphanolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levorphanol.
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LidocaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Lidocaine.
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LithiumThe risk or severity of adverse effects can be increased when Thalidomide is combined with Lithium.
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LofentanilThe risk or severity of adverse effects can be increased when Thalidomide is combined with Lofentanil.
LopinavirThe metabolism of Thalidomide can be increased when combined with Lopinavir.
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LoratadineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Loratadine.
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LorazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Lorazepam.
LosartanThe metabolism of Thalidomide can be decreased when combined with Losartan.
LovastatinThe metabolism of Thalidomide can be decreased when combined with Lovastatin.
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LoxapineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Loxapine.
Lu AA21004Lu AA21004 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Lu AA21004The risk or severity of adverse effects can be increased when Thalidomide is combined with Lu AA21004.
LuliconazoleThe serum concentration of Thalidomide can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Thalidomide can be decreased when it is combined with Lumacaftor.
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
LurasidoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Magnesium Sulfate.
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MaprotilineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Maprotiline.
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MeclizineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Meclizine.
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MedetomidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Medetomidine.
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MelatoninThe risk or severity of adverse effects can be increased when Thalidomide is combined with Melatonin.
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MelperoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Melperone.
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MepivacaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Mepivacaine.
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MeprobamateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Meprobamate.
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MesoridazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Mesoridazine.
MestranolMestranol may increase the thrombogenic activities of Thalidomide.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Thalidomide.
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MetaxaloneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Metaxalone.
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MethadoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methadone.
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methadyl Acetate.
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MethapyrileneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methapyrilene.
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MethaqualoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methaqualone.
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MethocarbamolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methocarbamol.
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MethohexitalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methotrimeprazine.
Methoxy polyethylene glycol-epoetin betaMethoxy polyethylene glycol-epoetin beta may increase the thrombogenic activities of Thalidomide.
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methoxyflurane.
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MethsuximideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methsuximide.
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methylphenobarbital.
MetyrosineThalidomide may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Thalidomide can be decreased when combined with Mexiletine.
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MidazolamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Midazolam.
MifepristoneThe serum concentration of Thalidomide can be increased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Thalidomide is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MirtazapineThalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MoclobemideThe metabolism of Thalidomide can be decreased when combined with Moclobemide.
ModafinilThe metabolism of Thalidomide can be decreased when combined with Modafinil.
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MolindoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Molindone.
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
MorphineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
NabiloneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nabilone.
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
NalbuphineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nalbuphine.
NatalizumabThe risk or severity of adverse effects can be increased when Thalidomide is combined with Natalizumab.
NelfinavirThe metabolism of Thalidomide can be decreased when combined with Nelfinavir.
NevirapineThe metabolism of Thalidomide can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Thalidomide can be decreased when combined with Nicardipine.
NicotineThe metabolism of Thalidomide can be decreased when combined with Nicotine.
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
NitrazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nitrazepam.
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Nitrous oxideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nitrous oxide.
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
NormethadoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Normethadone.
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
NortriptylineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nortriptyline.
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
OlanzapineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Olanzapine.
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
OlopatadineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Olopatadine.
OmeprazoleThe metabolism of Thalidomide can be decreased when combined with Omeprazole.
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
OndansetronThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ondansetron.
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
OpiumThe risk or severity of adverse effects can be increased when Thalidomide is combined with Opium.
OrphenadrineThalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
OsanetantThe risk or severity of adverse effects can be increased when Thalidomide is combined with Osanetant.
OsimertinibThe serum concentration of Thalidomide can be decreased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Thalidomide.
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
OxazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Oxazepam.
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
OxprenololThe risk or severity of adverse effects can be increased when Thalidomide is combined with Oxprenolol.
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
OxybuprocaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Oxybuprocaine.
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
OxycodoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Oxycodone.
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
OxymorphoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Oxymorphone.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thalidomide.
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PaliperidoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Paliperidone.
PamidronateThalidomide may increase the nephrotoxic activities of Pamidronate.
PantoprazoleThe metabolism of Thalidomide can be decreased when combined with Pantoprazole.
ParaldehydeThalidomide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Thalidomide can be increased when it is combined with Peginterferon alfa-2b.
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PentazocineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pentazocine.
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PentobarbitalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pentobarbital.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PerampanelThe risk or severity of adverse effects can be increased when Thalidomide is combined with Perampanel.
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PerospironeThe risk or severity of adverse effects can be increased when Thalidomide is combined with Perospirone.
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PerphenazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Perphenazine.
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PethidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pethidine.
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PhenobarbitalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Phenobarbital.
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Phenoxyethanol.
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PhenytoinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Phenytoin.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Thalidomide.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Thalidomide.
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PimozideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pimozide.
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PipamperoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pipamperone.
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PipotiazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pipotiazine.
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PizotifenThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pizotifen.
Polyestradiol phosphatePolyestradiol phosphate may increase the thrombogenic activities of Thalidomide.
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PomalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pomalidomide.
PramipexoleThalidomide may increase the sedative activities of Pramipexole.
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PramocaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pramocaine.
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PrazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Prazepam.
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PregabalinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pregabalin.
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PrilocaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Prilocaine.
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PrimidoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Primidone.
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ProcaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Procaine.
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ProchlorperazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Prochlorperazine.
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PromazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Promazine.
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PromethazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Promethazine.
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ProparacaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Proparacaine.
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PropofolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Propofol.
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PropoxycaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Propoxycaine.
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ProtriptylineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Protriptyline.
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
PSD502The risk or severity of adverse effects can be increased when Thalidomide is combined with PSD502.
PyrimethamineThe metabolism of Thalidomide can be decreased when combined with Pyrimethamine.
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
QuazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Quazepam.
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
QuetiapineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Quetiapine.
QuinestrolQuinestrol may increase the thrombogenic activities of Thalidomide.
QuinineThe metabolism of Thalidomide can be decreased when combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Rabies vaccine.
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
RamelteonThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ramelteon.
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
RemifentanilThe risk or severity of adverse effects can be increased when Thalidomide is combined with Remifentanil.
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
RemoxiprideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Remoxipride.
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ReserpineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Reserpine.
RifampicinThe metabolism of Thalidomide can be increased when combined with Rifampicin.
RifapentineThe metabolism of Thalidomide can be increased when combined with Rifapentine.
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
RisperidoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Risperidone.
RoflumilastRoflumilast may increase the immunosuppressive activities of Thalidomide.
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
RomifidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Romifidine.
RopiniroleThalidomide may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Thalidomide can be decreased when combined with Ropinirole.
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
RopivacaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ropivacaine.
RotigotineThalidomide may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thalidomide.
S-EthylisothioureaS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Thalidomide is combined with S-Ethylisothiourea.
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ScopolamineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Scopolamine.
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
SecobarbitalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Secobarbital.
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
SertindoleThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sertraline.
SertralineThe metabolism of Thalidomide can be decreased when combined with Sertraline.
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
SevofluraneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sevoflurane.
SildenafilThe metabolism of Thalidomide can be decreased when combined with Sildenafil.
SimeprevirThe metabolism of Thalidomide can be decreased when combined with Simeprevir.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Thalidomide.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Sodium oxybateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sodium oxybate.
SorafenibThe metabolism of Thalidomide can be decreased when combined with Sorafenib.
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
StiripentolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Stiripentol.
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
SufentanilThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sufentanil.
SulfadiazineThe metabolism of Thalidomide can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Thalidomide can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Thalidomide can be decreased when combined with Sulfisoxazole.
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
SulpirideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sulpiride.
SuvorexantSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
SuvorexantThe risk or severity of adverse effects can be increased when Thalidomide is combined with Suvorexant.
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may increase the thrombogenic activities of Thalidomide.
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Thalidomide.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Thalidomide.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TapentadolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tapentadol.
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TasimelteonThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tasimelteon.
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TemazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Temazepam.
TenofovirThe metabolism of Thalidomide can be decreased when combined with Tenofovir.
TeriflunomideThe serum concentration of Thalidomide can be decreased when it is combined with Teriflunomide.
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tetrabenazine.
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TetracaineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tetracaine.
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TetrodotoxinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tetrodotoxin.
TheophyllineThe metabolism of Thalidomide can be decreased when combined with Theophylline.
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThiamylalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Thiamylal.
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThiopentalThe risk or severity of adverse effects can be increased when Thalidomide is combined with Thiopental.
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Thioridazine.
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThiothixeneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Thiothixene.
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TiagabineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tiagabine.
TiboloneTibolone may increase the thrombogenic activities of Thalidomide.
TicagrelorThe metabolism of Thalidomide can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Thalidomide can be decreased when combined with Ticlopidine.
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TiletamineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tiletamine.
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TizanidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tizanidine.
TofacitinibThalidomide may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe metabolism of Thalidomide can be decreased when combined with Tolbutamide.
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TolcaponeThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tolcapone.
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TopiramateThe risk or severity of adverse effects can be increased when Thalidomide is combined with Topiramate.
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TramadolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tramadol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TranylcypromineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tranylcypromine.
TrastuzumabTrastuzumab may increase the neutropenic activities of Thalidomide.
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TrazodoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Trazodone.
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TriazolamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Triazolam.
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TriflupromazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Triflupromazine.
TrimethoprimThe metabolism of Thalidomide can be decreased when combined with Trimethoprim.
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TrimipramineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Trimipramine.
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TriprolidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Triprolidine.
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Valproic AcidThe risk or severity of adverse effects can be increased when Thalidomide is combined with Valproic Acid.
ValsartanThe metabolism of Thalidomide can be decreased when combined with Valsartan.
VemurafenibThe serum concentration of Thalidomide can be increased when it is combined with Vemurafenib.
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
VigabatrinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Vilazodone.
VoriconazoleThe metabolism of Thalidomide can be decreased when combined with Voriconazole.
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
VortioxetineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Vortioxetine.
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
XylazineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Xylazine.
ZafirlukastThe metabolism of Thalidomide can be decreased when combined with Zafirlukast.
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ZaleplonThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zaleplon.
ZeranolZeranol may increase the thrombogenic activities of Thalidomide.
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ZiconotideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ZiprasidoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ziprasidone.
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ZolazepamThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zolazepam.
Zoledronic acidThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zoledronic acid.
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ZolpidemThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zolpidem.
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ZonisamideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zonisamide.
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ZopicloneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zopiclone.
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ZotepineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zotepine.
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly an...
Gene Name:
CRBN
Uniprot ID:
Q96SW2
Molecular Weight:
50545.375 Da
References
  1. Zhu YX, Kortuem KM, Stewart AK: Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28. [PubMed:22966948 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
References
  1. Richardson P, Hideshima T, Anderson K: Thalidomide in multiple myeloma. Biomed Pharmacother. 2002 May;56(3):115-28. [PubMed:12046682 ]
  2. Fu LM, Fu-Liu CS: Thalidomide and tuberculosis. Int J Tuberc Lung Dis. 2002 Jul;6(7):569-72. [PubMed:12102294 ]
  3. Enomoto N, Takei Y, Hirose M, Ikejima K, Miwa H, Kitamura T, Sato N: Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology. 2002 Jul;123(1):291-300. [PubMed:12105857 ]
  4. Rajkumar SV: Thalidomide in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2001 Jun;1(1):20-8. [PubMed:12113124 ]
  5. Vescovo G, Ravara B, Angelini A, Sandri M, Carraro U, Ceconi C, Dalla Libera L: Effect of thalidomide on the skeletal muscle in experimental heart failure. Eur J Heart Fail. 2002 Aug;4(4):455-60. [PubMed:12167383 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Turk BE, Jiang H, Liu JO: Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7552-6. [PubMed:8755512 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transcriptional repressor activity, rna polymerase ii transcription regulatory region sequence-specific binding
Specific Function:
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-co...
Gene Name:
NFKB1
Uniprot ID:
P19838
Molecular Weight:
105355.175 Da
References
  1. Yasui K, Kobayashi N, Yamazaki T, Agematsu K: Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr Pharm Des. 2005;11(3):395-401. [PubMed:15723633 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
4. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Stephens TD, Bunde CJ, Fillmore BJ: Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol. 2000 Jun 15;59(12):1489-99. [PubMed:10799645 ]
  2. Shoji A, Kuwahara M, Ozaki H, Sawai H: Modified DNA aptamer that binds the (R)-isomer of a thalidomide derivative with high enantioselectivity. J Am Chem Soc. 2007 Feb 7;129(5):1456-64. [PubMed:17263432 ]
  3. Stephens TD, Fillmore BJ: Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology. 2000 Mar;61(3):189-95. [PubMed:10661908 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an...
Gene Name:
FGFR2
Uniprot ID:
P21802
Molecular Weight:
92024.29 Da
References
  1. Eichholz A, Merchant S, Gaya AM: Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther. 2010 Jun 24;3:69-82. [PubMed:20616958 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Horrobin DF: A low toxicity maintenance regime, using eicosapentaenoic acid and readily available drugs, for mantle cell lymphoma and other malignancies with excess cyclin D1 levels. Med Hypotheses. 2003 May;60(5):615-23. [PubMed:12710892 ]
  2. Hada M, Mizutari K: [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan]. Gan To Kagaku Ryoho. 2004 Sep;31(9):1407-10. [PubMed:15446566 ]
  3. Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004 Aug;230(2):81-8. [PubMed:15598423 ]
  4. Wiedmann MW, Caca K: Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets. 2005 May;5(3):171-93. [PubMed:15892618 ]
  5. Du GJ, Lin HH, Xu QT, Wang MW: Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol. 2005 Aug;43(2):112-9. [PubMed:15982930 ]
  6. Kim JH, Scialli AR: Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011 Jul;122(1):1-6. doi: 10.1093/toxsci/kfr088. Epub 2011 Apr 19. [PubMed:21507989 ]
7. Nuclear factor kappa-light-chain-enhancer of activated B cells
Kind
Protein
Organism
Human
Pharmacological action
unknown
References
  1. Kim JH, Scialli AR: Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011 Jul;122(1):1-6. doi: 10.1093/toxsci/kfr088. Epub 2011 Apr 19. [PubMed:21507989 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Components:
NameUniProt IDDetails
Alpha-1-acid glycoprotein 1P02763 Details
Alpha-1-acid glycoprotein 2P19652 Details
References
  1. Turk BE, Jiang H, Liu JO: Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7552-6. [PubMed:8755512 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 02:25